Semaglutide cuts kidney failure and death in people with diabetes and kidney disease
Published · Researched 2026-09-22
What happened (dated facts)
In the Phase 3b FLOW trial — 3,533 adults with type 2 diabetes and chronic kidney disease — weekly semaglutide 1.0 mg, reported in the New England Journal of Medicine in May 2024, reduced the composite of major kidney events, cardiovascular death, and kidney death by 24%, cut major adverse cardiovascular events by 18%, and lowered all-cause mortality by 20% versus placebo. The trial was stopped early in October 2023 on the recommendation of its data monitoring committee after an interim analysis showed clear efficacy. This was the first GLP-1 trial dedicated to a hard kidney-outcome endpoint.
Why it is genuinely positive
Diabetic kidney disease drives people to dialysis and early death, and until now nothing slowed it much beyond blood-pressure drugs. A weekly injection that cuts kidney failure, heart events, and death itself by a fifth to a quarter — so decisively the trial was stopped early — is a genuine lifesaver for one of medicine's highest-risk populations.
Social pulse
On Threads (searched 2026-09-22), the FLOW results were highlighted by the journal itself: @nejm posted "Notable Articles of 2024: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) — In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and deat[h]." The trial is circulating on social via the publishing journal's own account.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Patient Care Online summary of the FLOW/NEJM results (https://www.patientcareonline.com/view/semaglutide-cuts-major-kidney-disease-risk-by-24-in-type-2-diabetes-chronic-kidney-disease). Proves: 3,533 patients; 24% composite reduction; 18% MACE reduction; 20% all-cause mortality reduction; stopped early October 2023.
- Social sources: Threads — @nejm (journal's own account highlighting the FLOW trial as a Notable Article of 2024). Proves: the trial results are circulating on social via the publishing journal.
- Positivity check: hard-outcome mortality/kidney benefits in a stopped-early-for-efficacy trial — genuine.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| Trial | FLOW, Phase 3b, n=3,533, T2D + CKD | Patient Care Online / NEJM | 2024-05 |
| Kidney/CV-death composite | 24% lower | FLOW via Patient Care Online | 2024-05 |
| MACE | 18% lower | FLOW via Patient Care Online | 2024-05 |
| All-cause mortality | 20% lower | FLOW via Patient Care Online | 2024-05 |
| Early stop | October 2023, for efficacy | Patient Care Online | 2023-10 |
UNVERIFIED points
- Social-layer posts about FLOW were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: Patient Care Online summary of the FLOW/NEJM results ( — retrieval date not recorded